Prof.

MIRANDOLA Prisco

Professore di I fascia
  • Curriculum Vitae
  • Teaching
  • Appointments
  • Research

Curriculum Prof. Mirandola Prisco
Born in Rovigo on 22/08/1969
MsC Biological Sciences (1992)

1. ACADEMIC POSITION:

Macro-sector 06N; competition sector 06N2; disciplinary scientific sector M-EDF / 02 (Methods and didactics of sports activities) FULL PROFESSOR from 21/12/2015

b) roles previously held

Macro-sector competition 05H, 05H2 area competition; scientific-disciplinary sector BIO/16 (Human Anatomy);
Associate Professor from 11/01/2009 (DR 925 of 04.05.2010) University of Parma, Faculty of Medicine, Department of Anatomy, Pharmacology and Forensic Medical Sciences
Assistant Professor from 1/11/2001 at the 'University of Parma, Faculty of Medicine, Department of Anatomy, Pharmacology and Forensic Medical Sciences

2. PUBBLICAZIONI SCIENTIFICHE:

Total number of publications = 102
H Index = 34
Citations Total numebr >3600 (Scopus)
Cumulative IF2018 > 620
IF2018 mean =6,3

d) Papers

1. Presta V, Galuppo L, Mirandola P, Galli D, Pozzi G, Zoni R, Capici S, Colucci ME, Veronesi L, Ambrosini L, Gobbi G, Vitale M, Pasquarella C. One-shoulder carrying school backpack strongly affects gait swing phase and pelvic tilt: a case study. Acta Biomed. 2020 Apr 10;91(3-S):168-170.

2. Melani A, Gobbi G, Galli D, Carubbi C, Masselli E, Neri LM, Giovinco G, Cicchella A, Galuppo L, Presta V, Vaccarezza M, Vitale M, Mirandola P. Muscle Activation in Traditional and Experimental Barbell Bench Press Exercise: A Potential New Tool for Fitness Maintenance. Sports (Basel). 2019 Oct 17;7(10).

3. 3: Ferioli M, Zauli G, Maiorano P, Milani D, Mirandola P, Neri LM. Role of physical exercise in the regulation of epigenetic mechanisms in inflammation, cancer, neurodegenerative diseases, and aging process. J Cell Physiol. 2019 Feb 14.

4. Martini D, Innocenti A, Cosentino C, Bedogni G, Zavaroni I, Ventura M, Galli D, Mirandola P, Vitale M, Dei Cas A, Bonadonna RC, Passeri G, Pruneti C, Del Rio D. Claimed effects, outcome variables and methods of measurement for health claims proposed under regulation (EC) 1924/2006 and related to cognitive function in adults. Arch Ital Biol. 2018 Jul 1;156(1-2):64-86.

5. Masselli E, Carubbi C, Cambò B, Pozzi G, Gobbi G, Mirandola P, Follini E, Pagliaro L, Di Marcantonio D, Bonatti F, Percesepe A, Sykes SM, Aversa F, Vitale M. The -2518 A/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic predisposition factor for secondary myelofibrosis and biomarker of disease severity. Leukemia. 2018 Oct;32(10):2266-2270.

6. Martini D, Innocenti A, Cosentino C, Bedogni G, Angelino D, Biasini B, Zavaroni I, Ventura M, Galli D, Mirandola P, Vitale M, Dei Cas A, Bonadonna RC, Passeri G, Pruneti C, Del Rio D. Claimed Effects, Outcome Variables and Methods of Measurement for Health Claims on Foods Related to Vision Proposed Under Regulation (EC) 1924/2006. Nutrients. 2018 Feb 14;10(2). pii: E211.

7. Martini D, Biasini B, Zavaroni I, Bedogni G, Musci M, Pruneti C, Passeri G, Ventura M, Galli D, Mirandola P, Vitale M, Dei Cas A, Bonadonna RC, Del Rio D. Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the area of blood glucose and insulin concentrations. Acta Diabetol. 2018 Apr;55(4):391-404.

8. Martini S, Pozzi G, Carubbi C, Masselli E, Galli D, Di Nuzzo S, Banchini A, Gobbi G, Vitale M, Mirandola P. PKCε promotes human Th17 differentiation: Implications in the pathophysiology of psoriasis. Eur J Immunol. 2018 Apr;48(4):644-654.

9. Biasini B, Marchi L, Angelino D, Bedogni G, Zavaroni I, Pruneti C, Galli D, Mirandola P, Vitale M, Dei Cas A, Bonadonna RC, Passeri G, Ventura M, Del Rio D, Martini D. Claimed effects, outcome variables and methods of measurement for health claims on foods related to the gastrointestinal tract proposed under regulation (EC) 1924/2006. Int J Food Sci Nutr. 2018 Jan 29:1-34.

10. Di Marcantonio D, Martinez E, Sidoli S, Vadaketh J, Nieborowska-Skorska M, Gupta A, Meadows JM, Ferraro F, Masselli E, Challen GA, Milsom MD, Scholl C, Fröhling S, Balachandran S, Skorski T, Garcia BA, Mirandola P, Gobbi G, Garzon R, Vitale M, Sykes SM. Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clin Cancer Res. 2018 Feb 1;24(3):608-618.

11. Martini S, Soliman T, Gobbi G, Mirandola P, Carubbi C, Masselli E, Pozzi G, Parker PJ, Vitale M. PKCε Controls Mitotic Progression by Regulating Centrosome Migration and Mitotic Spindle Assembly. Mol Cancer Res. 2018 Jan;16(1):3-15.

12. Martini D, Angelino D, Cortelazzi C, Zavaroni I, Bedogni G, Musci M, Pruneti C, Passeri G, Ventura M, Galli D, Mirandola P, Vitale M, Dei Cas A, Bonadonna RC, Di Nuzzo S, De Felici MB, Del Rio D. Claimed Effects, Outcome Variables and Methods of Measurement for Health Claims Proposed Under European Community Regulation 1924/2006 in the Framework of Maintenance of Skin Function. Nutrients. 2017 Dec 22;10(1). pii: E7.

13. Martini D, Biasini B, Rossi S, Zavaroni I, Bedogni G, Musci M, Pruneti C, Passeri G, Ventura M, Galli D, Mirandola P, Vitale M, Dei Cas A, Bonadonna RC, Del Rio D. Claimed effects, outcome variables and methods of measurement for health claims on foods proposed under European Community Regulation 1924/2006 in the area of appetite ratings and weight management. Int J Food Sci Nutr. 2017 Sep 28:1-21.

14. Masselli E, Carubbi C, Pozzi G, Martini S, Aversa F, Galli D, Gobbi G, Mirandola P, Vitale M. Platelet expression of PKCepsilon oncoprotein in myelofibrosis is associated with disease severity and thrombotic risk. Ann Transl Med. 2017 Jul;5(13):273.

15. Martini D, Rossi S, Biasini B, Zavaroni I, Bedogni G, Musci M, Pruneti C, Passeri G, Ventura M, Di Nuzzo S, Galli D, Mirandola P, Vitale M, Dei Cas A, Bonadonna RC, Del Rio D. Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the framework of protection against oxidative damage and cardiovascular health. Nutr Metab Cardiovasc Dis. 2017 Jun;27(6):473-503..

16. Carubbi C, Masselli E, Martini S, Galli D, Aversa F, Mirandola P, Italiano JE Jr, Gobbi G, Vitale M. Human thrombopoiesis depends on Protein kinase Cδ/protein kinase Cε functional couple. Haematologica. 2016 Jul;101(7):812-20.

17. Queirolo V, Galli D, Masselli E, Borzì RM, Martini S, Vitale F, Gobbi G, Carubbi C, Mirandola P. PKCε is a regulator of hypertrophic differentiation of chondrocytes in osteoarthritis. Osteoarthritis Cartilage. 2016 Aug;24(8):1451-60.

18. Stellari F, Sala A, Ruscitti F, Carnini C, Mirandola P, Vitale M, Civelli M, Villetti G. Monitoring inflammation and airway remodeling by fluorescence molecular tomography in a chronic asthma model. J Transl Med. 2015 Oct 24;13:336..

19. Di Marcantonio D, Galli D, Carubbi C, Gobbi G, Queirolo V, Martini S, Merighi S, Vaccarezza M, Maffulli N, Sykes SM, Vitale M, Mirandola P. PKCε as a novel promoter of skeletal muscle differentiation and regeneration. Exp Cell Res. 2015 Nov 15;339(1):10-9..

20. Masselli E, Carubbi C, Gobbi G, Mirandola P, Galli D, Martini S, Bonomini S, Crugnola M, Craviotto L, Aversa F, Vitale M. Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients. Leukemia. 2015 Nov;29(11):2192-201.

21. Galli D, Carubbi C, Masselli E, Corradi D, Dei Cas A, Nouvenne A, Bucci G, Arcari ML, Mirandola P, Vitale M, Gobbi G. PKCε is a negative regulator of PVAT-derived vessel formation. Exp Cell Res. 2015 Jan 15;330(2):277-86.

22. Carubbi C, Masselli E, Nouvenne A, Russo D, Galli D, Mirandola P, Gobbi G, Vitale M. Laboratory diagnostics of inherited platelet disorders. Clin Chem Lab Med. 2014 Aug;52(8):1091-106..

23. Carubbi C, Masselli E, Gesi M, Galli D, Mirandola P, Vitale M, Gobbi G. Cytofluorimetric platelet analysis. Semin Thromb Hemost. 2014 Feb;40(1):88-98.

24. Gobbi G, Mirandola P, Carubbi C, Masselli E, Sykes SM, Ferraro F, Nouvenne A, Thon JN, Italiano JE Jr, Vitale M. Proplatelet generation in the mouse requires PKCε-dependent RhoA inhibition. Blood. 2013 Aug 15;122(7):1305-11..

25. Mirandola P, Gobbi G, Malinverno C, Carubbi C, Ferné FM, Artico M, Vitale M, Vaccarezza M. Impact of sulphurous water politzer inhalation on audiometric parameters in children with otitis media with effusion. Clin Exp Otorhinolaryngol. 2013 Mar;6(1):7-11.

26. Arcangeletti MC, Germini D, Rodighiero I, Mirandola P, De Conto F, Medici MC, Gatti R, Chezzi C, Calderaro A. Toll-like receptor 4 is involved in the cell cycle modulation and required for effective human cytomegalovirus infection in THP-1 macrophages. Virology. 2013 May 25;440(1):19-30. doi: 10.1016/j.virol.2013.01.021. Epub 2013 Mar 13. PubMed PMID: 23497941.

27. Gobbi G, Mirandola P, Carubbi C, Galli D, Vitale M. Protein kinase C ε in hematopoiesis: conductor or selector? Semin Thromb Hemost. 2013 Feb;39(1):59-65. doi: 10.1055/s-0032-1331156. Epub 2012 Dec 24. Review. PubMed PMID: 23266964.

28. Carubbi C, Mirandola P, Mattioli M, Galli D, Marziliano N, Merlini PA, Lina D, Notarangelo F, Cozzi MR, Gesi M, Ardissino D, De Marco L, Vitale M, Gobbi G. Protein kinase C ε expression in platelets from patients with acute myocardial infarction. PLoS One. 2012;7(10):e46409. doi: 10.1371/journal.pone.0046409. Epub 2012 Oct 5. PubMed PMID: 23071564; PubMed Central PMCID: PMC3465320.

29. Galli D, Gobbi G, Carrubbi C, Di Marcantonio D, Benedetti L, De Angelis MG, Meschi T, Vaccarezza M, Sampaolesi M, Mirandola P, Vitale M. The role of PKCε-dependent signaling for cardiac differentiation. Histochem Cell Biol. 2012 Aug 31. Doi: 10.1007/s00418-012-1022-4.

30. Gessi S, Merighi S, Stefanelli A, Mirandola P, Bonfatti A, Fini S, Sensi A, Marci R, Varani K, Borea PA, Vesce F. Downregulation of A(1) and A(2B) adenosine receptors in human trisomy 21 mesenchymal cells from first-trimester chorionic villi. Biochim Biophys Acta. 2012 Nov;1822(11):1660-70.

31. Dozza B, Gobbi G, Lucarelli E, Pierini M, Bella CD, Frisoni T, Tazzari PL, Ricci F, Mirandola P, Carubbi C, Giannini S, Donati D, Vitale M. A rapid method for obtaining mesenchymal stem cells and platelets from bone marrow aspirate. J Tissue Eng Regen Med. 2012 Jun 19. doi: 10.1002/term.1551.

32. Merighi S, Gessi S, Varani K, Fazzi D, Mirandola P, Borea PA. Cannabinoid
CB(2) receptor attenuates morphine-induced inflammatory responses in activated microglial cells. Br J Pharmacol. 2012 Aug;166(8):2371-85.

33. Galli D, Volta E, Milioli M, Mirandola P, Vanelli M, Brighenti F, Micheloni C, Vaccarezza M, Vitale M, Gobbi G. Anthropometric outcomes associated with a primary school-based health promotion programme in the Italian city of Parma. Sport Sciences For Health, 2012 April; 7(1):41-46.

34. Merighi S, Gessi S, Varani K, Simioni C, Fazzi D, Mirandola P, Borea PA. Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide. Br J Pharmacol. 2012 Mar;165(6):1773-88. doi: 10.1111/j.1476-5381.2011.01673.x.

35. Gobbi G, Di Marcantonio D, Micheloni C, Carubbi C, Galli D, Vaccarezza M, Bucci G, Vitale M, Mirandola P. TRAIL up-regulation must be accompanied by a reciprocal PKCε down-regulation during differentiation of colonic epithelial cell: implications for colorectal cancer cell differentiation. J Cell Physiol. 2012 Feb;227(2):630-8.

36. Mirandola P, Gobbi G, Masselli E, Micheloni C, Di Marcantonio D, Queirolo V, Chiodera P, Meschi T, Vitale M. Protein kinase Cε regulates proliferation and cell sensitivity to TGF-1β of CD4+ T lymphocytes: implications for Hashimoto thyroiditis. J Immunol. 2011 Nov 1;187(9):4721-32.

37. Mirandola P, Gobbi G, Micheloni C, Vaccarezza M, Di Marcantonio D, Ruscitti F, de Panfilis G, Vitale M. Hydrogen sulfide inhibits IL-8 expression in human keratinocytes via MAP kinase signaling. Lab Invest. 2011 Aug;91(8):1188-94.

38. Arcangeletti MC, Rodighiero I, Mirandola P, De Conto F, Covan S, Germini D, Razin S, Dettori G, Chezzi C. Cell-cycle-dependent localization of human cytomegalovirus UL83 phosphoprotein in the nucleolus and modulation of viral gene expression in human embryo fibroblasts in vitro. J Cell Biochem. 2011 Jan;112(1):307-17.

39. Gobbi G, Masselli E, Micheloni C, Nouvenne A, Russo D, Santi P, Matteucci A, Cocco L, Vitale M, Mirandola P. Hypoxia-induced down-modulation of PKCepsilon promotes trail-mediated apoptosis of tumor cells. Int J Oncol. 2010 Sep;37(3):719-29.

40. Merighi S, Simioni C, Gessi S, Varani K, Mirandola P, Tabrizi MA, Baraldi PG, Borea PA. A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia. 2009 Oct;11(10):1064-73.

41. Zamai L, Galeotti L, Zotto GD, Canonico B, Mirandola P, Papa S. Identification of a NCR+/NKG2D+/LFA-1(low)/CD94(-) immature human NK cell subset. Cytometry A. 2009 Nov;75(11):893-901.

42. Gobbi G, Ricci F, Malinverno C, Carubbi C, Pambianco M, Panfilis G, Vitale M, Mirandola P. Hydrogen sulfide impairs keratinocyte cell growth and adhesion inhibiting mitogen-activated protein kinase signaling. Lab Invest. 2009 Sep;89(9):994-1006.

43. Mirandola P, Gobbi G, Sponzilli I, Malinverno C, Cavazzoni A, Alfieri R, Petronini PG, Vitale M. TRAIL-induced apoptosis of FHIT-negative lung cancer cells is inhibited by FHIT re-expression. J Cell Physiol. 2009 Aug;220(2):492-8.

44. Gobbi G, Mirandola P, Carubbi C, Micheloni C, Malinverno C, Lunghi P, Bonati A, Vitale M. Phorbol ester-induced PKCepsilon down-modulation sensitizes AML cells to TRAIL-induced apoptosis and cell differentiation. Blood. 2009 Mar 26;113(13):3080-7.

45. Gobbi G, Mirandola P, Malinverno C, Sponzilli I, Carubbi C, Ricci F, Binazzi R, Basso G, Giuliani-Piccari G, Ramazzotti G, Pasquantonio G, Cocco L, Vitale M. Aberrant expression of B203.13 antigen in acute lymphoid leukemia of B-cell origin. Int J Oncol. 2008 Aug;33(2):371-4.

46. Chiodera P, Volta E, Gobbi G, Milioli MA, Mirandola P, Bonetti A, Delsignore R, Bernasconi S, Anedda A, Vitale M. Specifically designed physical exercise programs improve children's motor abilities. Scand J Med Sci Sports. 2008 Apr;18(2):179-87.

47. Toni R, Mirandola P, Gobbi G, Vitale M. Neuroendocrine regulation and tumor immunity. Eur J Histochem. 2007;51 Suppl 1:133-8.

48. Gobbi G, Mirandola P, Sponzilli I, Micheloni C, Malinverno C, Cocco L, Vitale M. Timing and expression level of protein kinase C epsilon regulate the megakaryocytic differentiation of human CD34 cells. Stem Cells. 2007 Sep;25(9):2322-9.

49. Mirandola P, Gobbi G, Sponzilli I, Pambianco M, Malinverno C, Cacchioli A, De Panfilis G, Vitale M. Exogenous hydrogen sulfide induces functional inhibition and cell death of cytotoxic lymphocytes subsets. J Cell Physiol. 2007 Dec;213(3):826-33.

50. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C, Leung E, Maclennan S, Baraldi PG, Borea PA. Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol. 2007 Aug;72(2):395-406.

51. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Baraldi PG, Borea PA. Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol Pharmacol. 2007 Jul;72(1):162-72.

52. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, Cocco L, Vitale M. NK cells and cancer. J Immunol. 2007 Apr 1;178(7):4011-6.

53. Gessi S, Merighi S, Varani K, Cattabriga E, Benini A, Mirandola P, Leung E, Mac Lennan S, Feo C, Baraldi S, Borea PA. Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A(3) adenosine subtype. J Cell Physiol. 2007 Jun;211(3):826-36.

54. Gobbi G, Sponzilli I, Mirandola P, Tazzari PL, Caimi L, Cacchioli A, Matteucci A, Giuliani Piccari G, Cocco L, Vitale M. Efficient platelet delta-granule release induced by [Ca2+]i elevation is modulated by GPIIbIIIa. Int J Mol Med. 2006 Aug;18(2):309-13.

55. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Baraldi PG, Borea PA. Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A₃ adenosine receptor. Purinergic Signal. 2006 Nov;2(4):627-32.

56. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Borea PA. Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochem Pharmacol. 2006 Jun 28;72(1):19-31.

57. Vitale M, Gobbi G, Mirandola P, Ponti C, Sponzilli I, Rinaldi L, Manzoli FA. TNF-related apoptosis-inducing ligand (TRAIL) and erythropoiesis: a role for PKC epsilon. Eur J Histochem. 2006 Jan-Mar;50(1):15-8.

58. Mirandola P, Sponzilli I, Solenghi E, Micheloni C, Rinaldi L, Gobbi G, Vitale M. Down-regulation of human leukocyte antigen class I and II and beta 2-microglobulin expression in human herpesvirus-7-infected cells. J Infect Dis. 2006 Apr 1;193(7):917-26.

59. Rinaldi L, Gobbi G, Pambianco M, Micheloni C, Mirandola P, Vitale M. Hydrogen sulfide prevents apoptosis of human PMN via inhibition of p38 and caspase 3. Lab Invest. 2006 Apr;86(4):391-7.

60. Mirandola P, Sponzilli I, Gobbi G, Marmiroli S, Rinaldi L, Binazzi R, Piccari GG, Ramazzotti G, Gaboardi GC, Cocco L, Vitale M. Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins. Int J Oncol. 2006 Jan;28(1):127-33.

61. Mirandola P, Gobbi G, Ponti C, Sponzilli I, Cocco L, Vitale M. PKCepsilon controls protection against TRAIL in erythroid progenitors. Blood. 2006 Jan 15;107(2):508-13.

62. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, MacLennan S, Baraldi PG, Borea PA. A3 adenosine receptors modulate hypoxia-inducible factor-1alpha expression in human A375 melanoma cells. Neoplasia. 2005 Oct;7(10):894-903.

63. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Borea PA. A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol Chem. 2005 May 20;280(20):19516-26.

64. Gobbi G, Mirandola P, Micheloni C, Solenghi E, Sponzilli I, Artico M, Soda G, Zanelli G, Pelusi G, Fiorini T, Cocco L, Vitale M. Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions. Int J Oncol. 2004 Dec;25(6):1625-9.

65. Mirandola P, Ponti C, Gobbi G, Sponzilli I, Melloni E, Vitale M. The response of human natural killer cells to interleukin-2. J Endocrinol Invest. 2004;27(6 Suppl):146-50.

66. Mirandola P, Ponti C, Gobbi G, Sponzilli I, Vaccarezza M, Cocco L, Zauli G, Secchiero P, Manzoli FA, Vitale M. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood. 2004 Oct 15;104(8):2418-24.

67. Gobbi G, Mirandola P, Tazzari PL, Talarico E, Caimi L, Martini G, Papa S, Conte R, Manzoli FA, Vitale M. New laboratory test in flow cytometry for the combined analysis of serologic and cellular parameters in the diagnosis of heparin-induced thrombocytopenia. Cytometry B Clin Cytom. 2004 Mar;58(1):32-8.

68. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA, Borea PA. A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther. 2003 Oct;100(1):31-48.

69. Merighi S, Mirandola P, Varani K, Gessi S, Capitani S, Leung E, Baraldi PG, Tabrizi MA, Borea PA. Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapic drugs: taxol and vindesine. Biochem Pharmacol. 2003 Sep 1;66(5):739-48.

70. Gobbi G, Mirandola P, Tazzari PL, Ricci F, Caimi L, Cacchioli A, Papa S, Conte R, Vitale M. Flow cytometry detection of serotonin content and release in resting and activated platelets. Br J Haematol. 2003 Jun;121(6):892-6.

71. Merighi S, Baraldi P.G, Gessi S, Iannotta V, Klotz K.N, Leung E, Mirandola P, Tabrizi M.A, Varani K, Borea P.A (2003). Adenosine Receptors and Human Melanoma. Drug Development Research 2003;58(4):377-385. doi: 10.1002/ddr.10181

72. Gonelli A, Mirandola P, Grill V, Secchiero P, Zauli G. Human herpesvirus 7 infection impairs the survival/differentiation of megakaryocytic cells. Haematologica. 2002 Nov;87(11):1223-5.

73. Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz KN, Leung E, Baraldi PG, Borea PA. Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol. 2002 Oct;119(4):923-33.

74. Secchiero P, Gonelli A, Mirandola P, Melloni E, Zamai L, Celeghini C, Milani D, Zauli G. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood. 2002 Oct 1;100(7):2421-9.

75. Vitale M, Bassini A, Secchiero P, Mirandola P, Ponti C, Zamai L, Mariani AR, Falconi M, Azzali G. NK-active cytokines IL-2, IL-12, and IL-15 selectively modulate specific protein kinase C (PKC) isoforms in primary human NK cells. Anat Rec. 2002 Feb 1;266(2):87-92.

76. Skrincosky D, Willis RA, Hocknell PK, Frelinger JG, Mirandola P, Wang X, Dewhurst S. Epitope mapping of human herpesvirus-7 gp65 using monoclonal antibodies. Arch Virol. 2001;146(9):1705-22.

77. Secchiero P, Mirandola P, Zella D, Celeghini C, Gonelli A, Vitale M, Capitani S, Zauli G. Human herpesvirus 7 induces the functional up-regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coupled to TRAIL-R1 down-modulation in CD4(+) T cells. Blood. 2001 Oct 15;98(8):2474-81.

78. Secchiero P, Gonelli A, Celeghini C, Mirandola P, Guidotti L, Visani G, Capitani S, Zauli G. Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. Blood. 2001 Oct 1;98(7):2220-8.

79. Curreli S, Romerio F, Mirandola P, Barion P, Bemis K, Zella D. Human primary CD4 + T cells activated in the presence of IFN-alpha 2b express functional indoleamine 2,3-dioxygenase. J Interferon Cytokine Res. 2001 Jun;21(6):431-7.

80. Zauli G, Milani D, Mirandola P, Mazzoni M, Secchiero P, Miscia S, Capitani S. HIV-1 Tat protein down-regulates CREB transcription factor expression in PC12 neuronal cells through a phosphatidylinositol 3-kinase/AKT/cyclic nucleoside phosphodiesterase pathway. FASEB J. 2001 Feb;15(2):483-91.

81. Secchiero P, Zella D, Curreli S, Mirandola P, Capitani S, Gallo RC, Zauli G. Engagement of CD28 modulates CXC chemokine receptor 4 surface expression in both resting and CD3-stimulated CD4+ T cells. J Immunol. 2000 Apr 15;164(8):4018-24.

82. Secchiero P, Zella D, Curreli S, Mirandola P, Capitani S, Gallo RC, Zauli G. Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication. Proc Natl Acad Sci U S A. 2000 Dec19;97(26):14620-5.

83. Mirandola P, Secchiero P, Pierpaoli S, Visani G, Zamai L, Vitale M, Capitani S, Zauli G. Infection of CD34(+) hematopoietic progenitor cells by human herpesvirus 7 (HHV-7). Blood. 2000 Jul 1;96(1):126-31.

84. Colamussi ML, Secchiero P, Zella D, Curreli S, Mirandola P, Capitani S, Zauli G. Stromal derived factor-1alpha induces apoptosis in activated primary CD4+ T cells. AIDS. 2000 Apr 14;14(6):748-50.

85. Zauli G, Secchiero P, Rodella L, Gibellini D, Mirandola P, Mazzoni M, Milani D, Dowd DR, Capitani S, Vitale M. HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. J Biol Chem. 2000 Feb11;275(6):4159-65.

86. Mirandola P, Stefan A, Brambilla E, Campadelli-Fiume G, Grimaldi LM. Absence of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients. Neurology. 1999 Oct 12;53(6):1367-8.

87. Mischiati C, Pironi F, Milani D, Giacca M, Mirandola P, Capitani S, Zauli G. Extracellular HIV-1 Tat protein differentially activates the JNK and ERK/MAPK pathways in CD4 T cells. AIDS. 1999 Sep 10;13(13):1637-45. PubMed PMID: 10509564.

88. Campadelli-Fiume G, Mirandola P, Menotti L. Human herpesvirus 6: An emerging pathogen. Emerg Infect Dis. 1999 May-Jun;5(3):353-66.

89. Menotti L, Mirandola P, Locati M, Campadelli-Fiume G. Trafficking to the plasma membrane of the seven-transmembrane protein encoded by human herpesvirus 6 U51 gene involves a cell-specific function present in T lymphocytes. J Virol. 1999 Jan;73(1):325-33.

90. Cocchi F, Menotti L, Mirandola P, Lopez M, Campadelli-Fiume G. The ectodomain of a novel member of the immunoglobulin subfamily related to the poliovirus receptor has the attributes of a bona fide receptor for herpes simplex virus types 1 and 2 in human cells. J Virol. 1998 Dec;72(12):9992-10002.

91. Kempf W, Adams V, Mirandola P, Menotti L, Di Luca D, Wey N, Müller B, Campadelli-Fiume G. Persistence of human herpesvirus 7 in normal tissues detected by expression of a structural antigen. J Infect Dis. 1998 Sep;178(3):841-5.

92. Mirandola P, Menegazzi P, Merighi S, Ravaioli T, Cassai E, Di Luca D. Temporal mapping of transcripts in herpesvirus 6 variants. J Virol. 1998 May;72(5):3837-44.

93. Mirandola P, Ravaioli T, Cassai E. PCR analysis of human telomeric repeats present on HHV-6A viral strains. Virus Genes. 1997;15(1):29-32.

94. Di Luca D, Mirandola P, Ravaioli T, Bigoni B, Cassai E. Distribution of HHV-6 variants in human tissues. Infect Agents Dis. 1996 Oct;5(4):203-14.

95. Dolcetti R, Di Luca D, Carbone A, Mirandola P, De Vita S, Vaccher E, Sighinolfi L, Gloghini A, Tirelli U, Cassai E, Boiocchi M. Human herpesvirus 6 in human immunodeficiency virus-infected individuals: association with early histologic phases of lymphadenopathy syndrome but not with malignant lymphoproliferative disorders. J Med Virol. 1996 Apr;48(4):344-53.

96. Di Luca D, Zorzenon M, Mirandola P, Colle R, Botta GA, Cassai E. Human herpesvirus 6 and human herpesvirus 7 in chronic fatigue syndrome. J Clin Microbiol. 1995 Jun;33(6):1660-61.

97. Di Luca D, Mirandola P, Ravaioli T, Dolcetti R, Frigatti A, Bovenzi P, Sighinolfi L, Monini P, Cassai E. Human herpesviruses 6 and 7 in salivary glands and shedding in saliva of healthy and human immunodeficiency virus positive individuals. J Med Virol. 1995 Apr;45(4):462-8.

98. Portolani M, Cermelli C, Mirandola P, Di Luca D. Isolation of human herpesvirus 7 from an infant with febrile syndrome. J Med Virol. 1995 Mar;45(3):282-3.

99. Dolcetti R, Di Luca D, Mirandola P, De Vita S, De Re V, Carbone A, Tirelli U, Cassai E, Boiocchi M. Frequent detection of human herpesvirus 6 DNA in HIV-associated lymphadenopathy. Lancet. 1994 Aug 20;344(8921):543.

100. Di Luca D, Dolcetti R, Mirandola P, De Re V, Secchiero P, Carbone A, Boiocchi M, Cassai E. Human herpesvirus 6: a survey of presence and variant distribution in normal peripheral lymphocytes and lymphoproliferative disorders. J Infect Dis.1994 Jul;170(1):211-5.

101. Bovenzi P, Mirandola P, Secchiero P, Strumia R, Cassai E, Di Luca D. Human herpesvirus 6 (variant A) in Kaposi's sarcoma. Lancet. 1993 May 15;341(8855):1288-9.

102. Di Luca D, Mirandola P, Secchiero P, Cermelli C, Aleotti A, Bovenzi P, Portolani M, Cassai E. Characterization of human herpesvirus 6 strains isolated from patients with exanthem subitum with or without cutaneous rash. J Infect Dis. 1992 Sep;166(3):689

3. RESEARCH AND FUDING

a) Coordination of international and national scientific research projects, admitted
funded after peer review;

2002 Progetto Giovani Ricercatori e Ricercatori Singoli, Università di Parma
2004 Fondo FIN (ex quota 40%) e FIL (ex quota 60%) - anno 2004
2005-2007 PRIN 2005 (MIUR), “Functional role of IL-4 receptor mutations on signaling and activation of lymphocytes in osteoarthritis”. National Coordinator: Meliconi, Laboratori di Genetica ed Immunogia, Istititi Ortopedici Rizzoli, Bologna. Local Unit PI Mirandola. Part of the scientific results of the project have been published in: J Immunol. 2007;178:4011-6, J Cell Physiol 2007;213:826-33.
2006 Fondo FIN (ex quota 40%) e FIL (ex quota 60%) – anno 2006 (60A05-8144); “TNF-alpha controls FHIT protein family apoptogenic effects in lung cancer cell.”. PI Mirandola: Part of the scientific results of the project have been published in: J Cell Phys. 2009;220:492-8.
2007 Fondo FIN (ex quota 40%) e FIL (ex quota 60%) – anno 2007 (FIL0719884); “TRAIL effects on hypoxic human tumor cells”. PI. Mirandola. Part of the scientific results of the project have been published in: Int J Oncol Int J Oncol. 2010 Sep;37(3):719-29.
2012 Programma di ricerca Regione-Università 2010-2012, Area 1 - Strategic Programmes “Progetto Regione Sanità “A tailored approach to the immune-monitoring and clinical management of viral and autoimmune diseases” Coordinatore Dr. Carlo Ferrari, della U.O. di malattie infettive ed epatologia dell’Azienda Ospedaliero-Universitaria di Parma. Ruolo del Prof. Mirandola: Responsabile del Work Package program “towards a more rational use of available anti-viral and immunomodulatory compounds and an individualized immunomonitoring”.
2016 Fondo FIL fondo locale per la ricerca di ateneo “Quota prodotti della ricerca bando 2016”

b) assignment of teaching duties or research (fellowship) at foreign, international, highly qualified the universities and research institutions;

1993-1994 Fellow C.N.R., progetto “F.A.T.M.A.”, at the Istituto di Microbiologia, Università di Ferrara.
1994-1996 Fellow I.S.S., progetto “AIDS Italia”, at the Istituto di Microbiologia, Università di Ferrara.
1996-1997 Fellow, (renewal) I.S.S., progetto “AIDS Italia”, at the Istituto di Microbiologia, Università di Ferrara.
1997-1999 Fellow U.E., progetto “Malattie infettive ed AIDS”, at the Dipartimento di Patologia Sperimentale, Università di Bologna.
1999-2000 Post. Doc. Fellow at the University of Maryland Biotechnology Institute (Baltimora, USA);

c) participation in academies having prestige in the sector;

Società Italiana di Anatomia e Istologia (SIAE)
Società Italiana delle Scienze Motorie e Sportive (SISMES)

g) awards for scientific activity;
2000 Cecilia Cioffrese award of the Fondazione Carlo Erba for studies and research in the field of health care, cancer and viral diseases

i) other qualifications

CELLULAR AND MOLECULAR BIOLOGY PhD at Dipartimento di Morfologia ed Embriologia, Università di Ferrara (2001).

4) INSTITUTIONAL APPOINTMENTS

a) Organization and Management

From 2014 to today PRESIDENT of the Degree Course in Sport and Health Sciences.

From 2017 SECRETARY of the National College of Full Professors of the SSC M-EDF/01 and M-EDF/02

From 2019 to today COORDINATOR of the pDH in Molecular Medicine, Department of Medicine and Surgery, University of Parma.

b) Didactic activity:
Since 2001, practical and in class teaching activities have been carried out in the BIO / 16 sector and subsequently BIO / 17 for the degree courses in the medical area, the health professions and the biological area. From 2014, teaching assignments in the M-EDF / 02 sector were obtained for the degree course in Sport and Health Sciences and for the CdLM Sciences and Techniques of Preventive and Adapted Motor Activities.

THEACHING ASSIGNMENTS

• assignment of BIOLOGY AND BIOTECHNOLOGY OF THE GAMETES, OF THE PRE-IMPLANTED EMBRYOS AND OF THE EMBRYONIC STEM CELLS - Study course: 5045 - MEDICAL, VETERINARY AND PHARMACEUTICAL BIOTECHNOLOGIES (BIO / 17);
• assignment of FUNCTIONAL ANATOMY OF THE STEM CELL NICHE - Course of study: 5045 - MEDICAL, VETERINARY AND PHARMACEUTICAL BIOTECHNOLOGY (BIO / 16);
• assignment of HUMAN ANATOMY - Study course: 5026 - MEDICINE AND SURGERY (BIO / 016);
• assignment of ADAPTED MOTOR EDUCATION - Study course: 5028 - SCIENCES AND TECHNIQUES OF PREVENTIVE AND ADAPTED MOTOR ACTIVITIES (M-EDF / 02);
• assignment of METHODS AND DIDACTICS OF MOTOR ACTIVITIES - Study course: 5026 - MEDICINE AND SURGERY (MED / 09);
• assignment of the THEORY AND METHODOLOGY OF MOTOR ACTIVITIES 2 (T.M.A.M./2) - Study course: 3019 - MOTOR SCIENCE, SPORT AND HEALTH (M-EDF / 02);
• assignment of PREVENTIVE AND COMPENSATIVE SPORT THEORY, TECHNIQUE AND DIDACTICS - Study course: 5028 - SCIENCES AND TECHNIQUES OF PREVENTIVE AND ADAPTED MOTOR ACTIVITIES (M-EDF / 02);
• didactic responsibility for REPRODUCTION AND STEM CELL BIOTECHNOLOGIES - Course of study: 5045 - MEDICAL, VETERINARY AND PHARMACEUTICAL BIOTECHNOLOGIES;
• didactic responsibility for SPORTS ACTIVITIES - Study course: 3019 - MOTOR SCIENCE, SPORT AND HEALTH;
• didactic responsibility of PHYSIOLOGY AND NEUROPHYSIOLOGY OF MOTOR CONTROL - Study course: 5028 - SCIENCES AND TECHNIQUES OF PREVENTIVE AND ADAPTED MOTOR ACTIVITIES;
• didactic responsibility for the REGENERATION OF DIFFERENTIATED TISSUES - Course of study: 5045 - MEDICAL, VETERINARY AND PHARMACEUTICAL BIOTECHNOLOGIES;
• didactic responsibility for THEORY, TECHNIQUE, DIDACTICS AND SPORT EVALUATION - Course of study: 5028 - SCIENCES AND TECHNIQUES OF PREVENTIVE AND ADAPTED MOTOR ACTIVITIES;
• didactic responsibility for TRAINING 3rd YEAR-1st SEM. EXTERNAL STRUCTURE - Study course: 3019 - MOTOR SCIENCE, SPORT AND HEALTH.

Parma il 05/05/2020

Anno accademico di erogazione: 2020/2021

Anno accademico di erogazione: 2019/2020

Anno accademico di erogazione: 2018/2019

Anno accademico di erogazione: 2017/2018

Anno accademico di erogazione: 2016/2017

Anno accademico di erogazione: 2015/2016

Anno accademico di erogazione: 2014/2015

Anno accademico di erogazione: 2013/2014

Professor/Teacher

Publications

Contacts

Phone number
033052